Skip to main content
Have a personal or library account? Click to login
Development and validation of a simple and sensitive size-exclusion chromatography method for quantitative determination of heparin in pharmaceuticals Cover

Development and validation of a simple and sensitive size-exclusion chromatography method for quantitative determination of heparin in pharmaceuticals

Open Access
|Mar 2015

References

  1. 1. J. Hirsh, Heparin, N. Engl. J. Med. 324 (1991) 1565-1574; DOI: 10.1056/NEJM199111283252213.
  2. 2. J. Hirsh, T. E. Warkentin, S. G. Ghaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. Magnus Ohman and J. E. Dalen, Heparin and low-molecular-weight heparin mechanisms of action, Pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest 119 (2001) 64S-94S; DOI: 10.1378/chest.119.1_suppl.64S.
  3. 3. A. B. Blann, M. J. Landray and G. Y. H. Lip, ABC of antithrombotic therapy: An overview of antithrombotic therapy, B.M.J 325 (2002) 762-765; DOI: 10.1136/bmj.325.7367.762.
  4. 4. J. Hirsh, A. K. Bauer, M. B. Donati, M. Gould, M. M. Samama and J. I. Weitz, Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed.), Chest 133 (2008) 141S-159S; DOI: 10.1378/chest.08-0689.
  5. 5. J. Hirsh, T. E. Warkentin, R. Raschke, C. Granger, E. Magnus Ohman and J. E. Dalen, Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety, Chest 114 (1998) 489S-510S; DOI: 10.1378/chest.114.5_ Supplement.489S.
  6. 6. A. Ziegler and J. Zaia, Size-exclusion chromatography of heparin oligosaccharides at high and low pressure, J. Chromatogr. B 837 (2006) 76-86; DOI: 10.1016/j.jchromb.2006.04.013.
  7. 7. S. Beni, J. F. K. Limtiaco and C. K. Larive, Analysis and characterization of heparin impurities, Anal. Bioanal. Chem. 399 (2011) 527-539; DOI: 10.1007/s00216-010-4121-x.
  8. 8. D. S. Weitz and J. I. Weitz, Update on heparin: what do we need to know?, J. Thromb. Thrombolysis 29 (2010) 199-207; DOI: 10.1007/s11239-009-0411-6.
  9. 9. A. K. Korir and C. K. Larive, Advances in the separation, sensitive detection, and characterization of heparin and heparan sulfate, Anal. Bioanal. Chem. 393 (2009) 155-169; DOI: 10.1007/s00216-008-2412-2.
  10. 10. W. Mao, C. Thanawiroon and R. J. Linhardt, Capillary electrophoresis for the analysis of glycosaminoglycans and glycosaminoglycan-derived oligosaccharides, Biomed. Chromatogr. 16 (2002) 77-94; DOI: 10.1002/bmc.153.
  11. 11. J. Beirne, H. Truchan and L. Rao, Development and qualifi cation of a size exclusion chromatography coupled with multiangle light sca_ ering method for molecular weight determination of unfractionated heparin, Anal. Bioanal. Chem. 399 (2011) 717-725; DOI: 10.1007/s00216-010-4187-5.
  12. 12. F. Zhang, B. Yang, M. Ly, K. Solakyildirim, Z. Xiao, Z. Wang, J. M. Beaudet, A. Y. Torelli, J. S. Dordick and R. J. Linhardt, Structural characterization of heparins from diff erent commercial sources, Anal. Bioanal. Chem. 401 (2011) 2793-2803; DOI: 10.1007/s00216-011-5367-7. 13. J. E. Knobloch and P. N. Shaklee, Absolute molecular weight distribution of low-molecular-weight heparins by size-exclusion chromatography with multiangle laser light sca_ ering detection, Anal. Biochem. 245 (1997) 231-241; DOI: 10.1006/abio.1996.9984.
  13. 14. X. Guo, M. Condra, K. Kimura, G. Berth, H. Dautzenberg and P. L. Dubin, Determination of molecular weight of heparin by size exclusion chromatography with universal calibration, Anal. Biochem. 312 (2003) 33-39; DOI: 10.1016/S0003-2697(02)00428-1.
  14. 15. S. Bertini, A. Bisio, G. Torri, D. Bensi and M. Terbojevich, Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array, Biomacromolecules 6 (2005) 168-173; DOI: 10.1021/bm049693s.
  15. 16. O. F. Swoap and M. H. Kuizenga, The sheep plasma method for the bioassay of heparin preparations, J. Am. Pharm. Assoc. 38 (1949) 563-565; DOI: 10.1002/jps.3030381012.
  16. 17. C. D. Sommers, N. Montpas, A. Adam and D. A. Keire, Characterization of currently marketed heparin products: adverse event relevant bioassays, J. Pharm. Biomed. Anal. 67-68 (2012) 28-35; DOI: 10.1016/j.jpba.2012.04.017.
  17. 18. European Pharmacopoeia, 8th ed., Vol. 2, Council of Europe, Strasbourg 2013, pp. 2390-2391.
  18. 19. United States Pharmacopoeia 36, National Formulary 31, Vol. 2, USP Convention, Rockville 2013, pp. 3801-3805.
  19. 20. P. K. Smith, A. K. Mallia and G. T. Hermanson, Colorimetric method for the assay of heparin content in immobilized heparin preparations, Anal. Biochem. 109 (1980) 466-473; DOI: 10.1016/0003-2697(80)90679-X.
  20. 21. I. Nemcova, P. Rychlovsky, M. Havelcova and M. Brabcova, Determination of heparin using flow injection analysis with spectrophotometric detection, Anal. Chim. Acta 401 (1999) 223-228; DOI: 10.1016/S0003-2670(99)00472-9.
  21. 22. A. Karewicz, K. Zasada, K. Szczubialka, S. Zapotoczny, R. Lach and M. Nowakowska, “Smart” alginate-hydroxypropylcellulose microbeads for controlled release of heparin, Int. J. Pharm. 385 (2010) 163-169; DOI: 10.1016/j.ij pharm.2009.10.021.
  22. 23. C. E. Doneanu and W. Chen, Impurity evaluation of heparin sodium by anion exchange chromatography, Waters Application Note, Milford (MA) 2009.
  23. 24. X. Xu, Y. Li, A. Cui and H. Chen, High Resolution Analysis of Heparin and Heparin-like Impurities on GlycomixTM - an Anion Exchange Column. Glycan separation, Sepax Application Note, Sepax Technologies, Delaware 2012.
  24. 25. M. L. Trehy, J. C. Reepmeyer, R. E. Kolinski, B. J. Westenberger and L. F. Buhse, Analysis of heparin sodium by SAX/HPLC for contaminants and impurities, J. Pharm. Biomed. Anal. 49 (2009) 670-673; DOI: 10.1016/j.jpba.2008.12.013.
  25. 26. D. A. Keire, M. L. Trehy, J. C. Reepmeyer, R. E. Kolinski, W. Ye, J. Dunn, B. J. Westenberger and L. F. Buhse, Analysis of crude heparin by 1H NMR, capillary electrophoresis, and strong-anion-exchange- HPLC for contamination by over sulfated chondroitin sulfate, J. Pharm. Biomed. Anal. 51 (2010) 921-926; DOI: 10.1016/j.jpba.2009.10.017.
  26. 27. D. A. Keire, D. J. Mans, H. Ye, R. E. Kolinski and L. F. Buhse, Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR, SAX-HPLC, and anticoagulation time approaches, J. Pharm. Biomed. Anal. 52 (2010) 656-664; DOI: 10.1016/j.jpba.2010.02.019.
  27. 28. M. Radivojša, I. Grabnar and P. Ahlin Grabnar, Thermoreversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: Design and in vitro evaluation, Eur. J. Pharm. Sci. 50 (2013) 93-101; DOI: 10.1016/j.ejps.2013.03.002.
  28. 29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva, November 2005.
  29. 30. Q. Jiao and Q. Liu, Mechanism of interference and Azur A response in the heparin assay, Anal. Le . 31 (1998) 1311-1323; DOI: 10.1080/00032719808002868.
DOI: https://doi.org/10.1515/acph-2015-0010 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 43 - 52
Submitted on: Oct 23, 2014
Published on: Mar 11, 2015
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2015 Maja Radivojša Matanović, Iztok Grabnarm, Pegi Ahlin Grabnar, Robert Roškar, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.